Groundbreaking genomic test could save millions of breast cancer patients from chemotherapyGuardian
VeraCyte genomic test identifies breast cancer patients who can skip chemoreuters
The landmark OPTIMA trial provides practice-changing evidence that Verasight’s ProSigna test identifies patients with high-risk breast cancer who can safely avoid chemotherapy.business wire
How Investors Are Reacting to Verasight (VCYT) ASCO Phase III Data and New Oncology Launch PlansSimplyWall.st
OPTIMA Phase III: Gene expression testing helps identify patients who may survive chemotherapyDocwire News
